

# The Contribution of Rapid Antigen Tests to the Diagnosis of Active SARS-CoV-2 Infection in Limited Resources Settings, Democratic Republic of the Congo

[Boniface Kaputa Kabala](#)\*, [Daniel Mukadi Bamuleka](#), [Julien Neze Sebakunzi](#), Delphine Mbonga Mande, Fiston Mboma Matalampaka, Jean Claude Changa Changa, Arthur Tshimuanga Kabuamba, Juslin Ntambue Kaneyi, Youdhie Ituneme N'kaflabo, François Kahwata Mawika, [Lisette Lebo Nsimba](#), Jean Paul Kompany Kisenzele, [Trésor Kabeya Mampuela](#), [Steve Ahuka Mundeke](#), Edith Nkwembe Ngabana

Posted Date: 26 November 2025

doi: 10.20944/preprints202511.2056.v1

Keywords: SARS-CoV-2; rapid antigen tests; diagnosis; limited resources; Democratic Republic of the Congo



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

# The Contribution of Rapid Antigen Tests to the Diagnosis of Active SARS-CoV-2 Infection in Limited Resources Settings, Democratic Republic of the Congo

Boniface Kaputa-Kabala <sup>1,2,\*</sup>, Daniel Mukadi-Bamuleka <sup>1,2,3</sup>, Julien Neze-Sebakunzi <sup>1</sup>, Delphine Mbonga -Mande <sup>2</sup>, Fiston Mboma-Matalampaka <sup>1,2</sup>, Jean Claude Changa-Changa <sup>2</sup>, Arthur Tshimuanga-Kabuamba <sup>5</sup>, Juslin Ntambue-Kaneyi <sup>4</sup>, Youdhie Ituneme-N'kaflabo <sup>1,2</sup>, François Kahwata-Mawika <sup>1,2</sup>, Lisette Lebo-Nsimba <sup>1,2</sup>, Jean Paul Kompany-Kisenzele <sup>1,2</sup>, Trésor Kabeya-Mampuela <sup>1,2</sup>, Steve Ahuka-Mundeke <sup>1,2,†</sup> and Edith Nkwembe-Ngabana <sup>1,2,†</sup>

- <sup>1</sup> Service of Microbiology, Department of Medical Biology, Kinshasa Teaching School of Medicine, University of Kinshasa, Kinshasa Mont Amba XI, Democratic Republic of the Congo
- <sup>2</sup> Department of Virology, National Institute for Biomedical Research (INRB), Kinshasa 1197, Democratic Republic of the Congo
- <sup>3</sup> Rodolphe Mérieux de l'INRB Goma Laboratory, Goma, North Kivu, Democratic Republic of the Congo
- <sup>4</sup> National Programme for the Control of Cholera and Diarrhoeal Diseases, Ministry of Public Health, Hygiene and Social Welfare, Democratic Republic of the Congo
- <sup>5</sup> School of Public Health, University of Lubumbashi, Democratic Republic of the Congo
- \* Correspondence: bonifacekaputa@gmail.com

## Abstract

In the context of a rapidly spreading pandemic, early detection of active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains essential to break the chain of transmission and limit associated complications. In the Democratic Republic of the Congo (DRC), access to nucleic acid amplification tests (NAATs), such as RT-PCR, remains limited due to logistical, technical, and financial constraints. The introduction of rapid antigen diagnostic tests (RATs) represented a major advance in strengthening diagnosis. We conducted a cross-sectional and retrospective observational study in Kinshasa to assess the operational and epidemiological contribution of RATs in detecting active SARS-CoV-2 infection. Two approved antigen tests (Panbio™ from Abbott and Standard Q™ from SD Biosensor), validated by the World Health Organization (WHO), the High Authority of Health (HAH) internationally and locally by the Institut National de Recherche Biomédicale (INRB). A total of 111,278 people suspected of infection were tested during the study period. Of these, 56,846 (51.1%) were diagnosed by RT-PCR, with a positivity rate of 30.2%, while 54,432 (48.9%) were tested by RATs, with a positivity rate of 16.8%. The male gender represented 59 780 (53.7%) and the female gender 51 498 (46.3%), with the estimated mean age at 36.9±15.9 years. The age group ≤ 21 years had the highest rate (19.1%), with a tendency for positivity to increase with age. Females had a slightly higher positivity rate than males (17.1% vs. 16.4%). All Health Zones in Kinshasa had deployed RATs, with the Barumbu Health Zone showing the highest positivity rate (37.8%). Fever (≥ 38°C) was the symptom most frequently associated with RATs positivity (16.5%). All other symptoms, including close contact with a confirmed case, showed a significant association with positivity, with the exception of dyspnea. RATs played a key role in the detection of SARS-CoV-2 during the third and fourth epidemic waves, complementing RT-PCR. These results highlight the relevance of their use in resource-limited settings to improve rapid detection and guide response strategies to emerging or re-emerging respiratory epidemic threats.

**Keywords:** SARS-CoV-2; rapid antigen tests; diagnosis; limited resources; Democratic Republic of the Congo

## 1. Introduction

On December 31, 2019, Wuhan city in China reported an outbreak of COVID-19 due to a new Coronavirus, later named SARS-CoV-2 [1,2]. This latter has quickly spread worldwide and led the WHO to declare the Covid-19 as a pandemic in March 2020 [3]. Due to important number of cases recorded worldwide, tremendous challenges arose regarding diagnostic tools availability, accessibility, and distribution. If the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) is still the reference standard for SARS-CoV-2, tool's high cost, technical requirements, and low availability hinders its use in poor resource settings such as the Democratic Republic of the Congo (DRC) [4–6].

At the beginning of the Covid-19 pandemic, only three provinces—Kinshasa, Haut-Katanga, and Nord-Kivu— had molecular testing capacity in DRC. However, this laboratory capacity was quickly overloaded by massive influx of samples coming from either unserved provinces or numerous health facilities in Kinshasa. The oversaturation of testing capacity, especially in Kinshasa, the epicenter of the outbreak has led the Covid-19 response leadership to envision using alternative and/or complementary methods such as rapid antigen tests for SARS-CoV-2 detection. Indeed, rapid antigen tests are cheaper, easy to handle, do not require sophisticated technical equipment, and reduces the turn-around time for results delivery to <30 minutes [7–11]. They can alleviate the workload in the laboratories, allow quick decision-making and facilitate a large-scale testing, especially in remote areas [12–14].

Over the course of the pandemic, the DRC Covid-19 response leadership has decentralized the diagnosis, including the use of RATs across different provinces, including in remote areas [15]. However, the real impact of RATs use on health system and community has not yet been broadly evaluated, and their potential contribution to the SARS-CoV-2 epidemiological surveillance remains poorly documented to date in DRC.

Evaluating the contribution of RATs in strengthening the diagnosis and surveillance of active SARS-CoV-2 infection during the COVID-19 pandemic, in order to guide public health decision-making and inform response strategies, especially in resource-limited settings.

This study aims to describe the epidemiological and operational contribution of RATs in the management of COVID-19 cases in Kinshasa and to explore the associations between clinical symptoms or exposure factors and RATs positivity

The study is not comparative with RT-PCR data, although RATs were used in addition to this reference test during this period. Furthermore, evaluating diagnostic performance was not among the objectives of this work.

## 2. Materials and Methods

### 2.1. Settings and Design

This cross-sectional and retrospective observational study was conducted in Kinshasa, the epicenter of Covid-19 pandemic in the DRC, from January 2021 to December 2022. This study was jointly implemented by the Kinshasa Health District Office and the Institut National de Recherche Biomédicale (INRB) as a part of the national epidemiological surveillance of SARS-CoV-2.

### 2.2. Population and Selection Criteria

We included consenting individuals temporarily or permanently living in Kinshasa who met following criteria: 1) responding to the WHO case definition for Covid-19 [16], 2) having a close contact with a suspected case and/or confirmed case, 3) staying in a high-risk transmission area, and 4) providing biological sample for RAT analysis. We excluded any subject who did not either consent or provide a biological specimen.



2.3. Data Collection and Analysis

Sociodemographic, clinical and epidemiological data were collected with EWARS® (Early Warning, Alert, and Response system) software based on the national case investigation form. Data were exported to Microsoft Excel 2016® (Microsoft, Redmon, WA, USA) for cleaning, and subsequently analyzed with STATA version 14.0 (Stata Corp, College Station, Texas 77845 USA (IBM, New York, USA)).

For descriptive analysis, we summarized sociodemographic, clinical and laboratory characteristics using frequency and percentages for categorical variables and means ± standard deviation for continuous variables. Epidemiological weeks were grouped by quarters to explore patterns.

In addition to the descriptive analyses, bivariate analysis using the Chi-square ( $\chi^2$ ) test, with a p-value < 0.05 as statistically significant, were performed to assess the association between sociodemographic or clinical variables and RATs positivity. These analyses were not intended for comparative evaluation between diagnostic method (RAT and RT-PCR).

For the spatial analysis, the mapping of suspected cases and the implementation of RATs in Health Zones was performed using QGIS software (Quantum Geographic Information System, version 3.30).

To facilitate the visualization of temporal patterns in RAT-based case detection across quarters, a linear multiplicative Min–Max scaling was applied to the quarterly RAT values. The Min–Max scaler rescaled each quarterly RAT value to the [0–1] interval using the formula :

$$X_{scaled} = \frac{X - X_{min}}{X_{max} - X_{min}}$$

This normalization was used exclusively for graphical representation, given the large amplitude of raw values over time. Raw values remained the only source for descriptive summaries, and no inferential comparative or cross-modality analysis was conducted using normalized data.

2.4. Sample Collection and Laboratory Procedures

Before sample collection, healthcare workers from participating facilities received standardized training covering COVID-19 basics, nasopharyngeal sampling, packing, storage, transportation, personal protective equipment(PPE) use, RATs procedure and result reporting through EWARS software (See Figure 1).




Figure 1. Algorithm for analysing suspected cases with RATs.

Quality control was systematically performed for each kit batch using the positive and negative controls before field use, to ensure the reliability of the results.

Two nasopharyngeal swabs were collected at the healthcare facilities or mobile sampling sites. The first swab was used immediately onsite for RATs analysis and discarded. The second swab was placed into a 3 ml viral transport medium tube (MTV), temporarily stored at +4°C and transported to the INRB for molecular analysis within a maximum of 72 hours. We used two lateral flow assays for the qualitative detection of the SARS-CoV-2, the Panbio COVID-19 Ag Rapid Test Device® (Abbott, Illinois, USA) and Standard Q COVID-19 Ag Test® (SD Biosensor, Republic of Korea). Both RATs had previously been approved by the WHO, then validated for use at the country level [17–20].

The analysis and interpretation were in accordance with the manufacturer's instructions. The interpretation included individual's clinical picture, medical history, recent exposure, and RATs read.

The test was positive whenever two red bands appeared, one in the test zone (T) and the other in the control zone (C). The test was negative if a single red band appears in the control zone (C). The test was invalid if the control band was absent. Invalid tests were repeated within 30 minutes; samples with repeated invalid results were reported as invalid.

Symptomatic individuals with more than seven days of symptoms and a negative RAT result were referred for confirmatory RT-PCR. In our decision-making, we considered that a negative result did not rule out a SARS-CoV-2 infection. Therefore, RT-PCR was used as the gold standard, especially for suspect-cases with a negative RAT.

However, samples collected directly at RT-PCR testing sites were analyzed by RT-PCR without prior RAT.


For RT-PCR, viral RNA was extracted using the DaAnGene RNA/DNA Purification kit (DaAnGene Co., Ltd, Guangzhou, China). SARS-CoV detection targeted the Nucleic acid amplification and ORF1ab genes using the DaAnGene Detection kit for 2019-nCoV (PCR-Fluorescence)

### 2.5. Ethical Considerations

This study was conducted as a part of the national Covid-19 response coordinated by the Secrétariat Technique du Comité Multisectoriel de Lutte contre la Covid-19. As such, formal ethical approval was not required; however, a formal letter of authorization was issued by the Health District Office (DPS) N°SM-700/CBCD/SEC/NM//037BCD/2023 and the Covid-19 response Incident Manager. Verbal informed consent and assent when applicable was obtained from for all participants' prior for testing. Data were handled in accordance with the national confidentiality and data protection regulations.

## 3. Results

We tested 111 278 suspect-cases, among which 56 846 (51.1%) diagnosed by RT-PCR with a positivity rate of 30.2% (n=17,191); while 54 432 (48.9%) were tested by RATs, for a positivity rate of 16.8% (n=9 126) (Figure 2). Of the 26 317 SARS-CoV-2 positive cases identified, 34.7% were detected by RATs and 65.3% by RT-PCR. Males represented 59 780 (53,7%) and females 51 498 (46,3%) of suspected cases. The estimated mean age was 36.9 15.9 years.



**Figure 2.** Diagram showing inclusion of suspected cases and procedure for obtaining results.


Among the 54 432 individuals testing using RATs, the 21–40 years’ age group was the most represented (n=27 221; 50%), followed by 41–60 years (n = 16 056; 29.5%), ≤ 21 years (n = 6 143; 11.3%), and ≥ 60 years (n = 5 012; 9.2%). The positivity rate decreased progressively with age, ranging from 19.1% in individuals ≤ 21 years to 13.8% in those ≥ 60 years.

Men represented 54,8% (n = 29 842), of those tested by RATs while women accounted for 45.2% (n=24 600). The positivity rate was 17.1% among women and 16.5% men, compared with women (45,2%). (table 1).


**Table 1.** Sociodemographic characteristics of suspected cases tested by antigen tests.

| Variables                               | N=54432 | Negative (%) | Positive (%) |
|-----------------------------------------|---------|--------------|--------------|
| <b>Age (years), mean age: 36.9±15.9</b> |         |              |              |
| ≤21                                     | 6143    | 4972 (80.9)  | 1171 (19.1)  |
| 21-40                                   | 27221   | 22435 (82.4) | 4786 (17.6)  |
| 41-60                                   | 16056   | 13581 (84.6) | 2475 (15.4)  |
| ≥60                                     | 5012    | 4318 (86.2)  | 694 (13.8)   |
| <b>Sex</b>                              |         |              |              |
| M                                       | 29832   | 24923 (83.5) | 4909 (16.5)  |
| F                                       | 24600   | 20383 (82.9) | 4217 (17.1)  |

Most Health Zones in Kinshasa actively used RATs for SARS-CoV-2 screening. The RATs positivity rate considerably varied between Health Zones (Figure 3 &Figure 4). Health Zones reporting highest positivity rate were Barumbu (37.8%), Lemba (28.0%), Binza Météo (26.3%), Limete (25.1%), Bumbu (22.5%), Bandalungwa (22.2%) and Ngaba (22.0%) (Figure 4).




**Figure 3.** Mapping of the implementation and suspected cases using RATs in the Kinshasa Provincial Health Division during the 2021-2022 COVID-19 Pandemic.



**Figure 4.** Distribution of SARS-CoV-2 detection rates (positivity) by RATs for each health zone.

Symptoms frequently reported included fever (41,079, %), headache (30,307, %) and cough (26,931, %), with 6,759 (%), 4,959 (%), and 4,412 (%) of positives, respectively (Figure 5).



**Figure 5.** Frequency of clinical signs and their positivity to RATs in suspected cases.

The most frequently reported symptoms among RAT-tested individuals were fever (41 079 cases), headache (30 307 cases) and cough (26 931 cases). (Figure 5).

Chi-square analyses demonstrated significant between several symptoms and RAT positivity (Table 2).

Rhinorrhea was strongly associated with a positive RAT result ( $p = 0.001$ ). In contrast dyspnea ( $\chi^2 = 3.178$ ;  $p = 0.075$ ) were not significantly associated with positivity. Other symptoms, such as cough, sore throat, physical asthenia, vomiting, nausea, diarrhea, joint pain and fever, were significantly associated with positive tests (all  $p < 0.05$ ).

Exposure history, whether contact with a symptomatic individual or with a confirmed COVID-19 case, was strongly associated with test positivity in our population ( $p < 0.001$ ).

Individuals with a reported exposure showed COVID-19 positivity rates approximately two to three times higher than those without exposure, and this association was consistent across both sexes (Table 2).

**Table 2.** Association between reported symptoms, exposure to suspected or confirmed COVID-19 cases, and test results.

| Variables   | N = 54432 | Negative [n (%)] | Positive [n (%)] | Chi-square | p-value |
|-------------|-----------|------------------|------------------|------------|---------|
| Symptoms    |           |                  |                  |            |         |
| Sore throat |           |                  |                  |            |         |
| No          | 51453     | 42710 (83)       | 8743 (17)        | 34.51      | < 0.001 |
| Yes         | 2979      | 2596 (87.1)      | 383 (12.9)       |            |         |
| Rhinorrhea  |           |                  |                  |            |         |
| No          | 42097     | 35158 (83.5)     | 6939 (16.5)      | 10.63      | 0.001   |
| Yes         | 12335     | 10148 (82.3)     | 2187 (17.7)      |            |         |
| Cough       |           |                  |                  |            |         |
| No          | 27501     | 22787 (82.9)     | 4714 (17.1)      | 5.61       | 0.018   |
| Yes         | 26931     | 22519 (83.6)     | 4412 (16.4)      |            |         |
| Dyspnea     |           |                  |                  |            |         |
| No          | 51267     | 42708 (83.3)     | 8559 (16.7)      | 3.18       | 0.075   |
| Yes         | 3165      | 2598 (82.1)      | 567 (17.9)       |            |         |

|                                                    |       |              |             |         |         |  |
|----------------------------------------------------|-------|--------------|-------------|---------|---------|--|
| Physical asthenia                                  |       |              |             |         |         |  |
| No                                                 | 42024 | 34817 (82.9) | 7207 (17.1) | 19.47   | < 0.001 |  |
| Yes                                                | 12408 | 10489 (84.5) | 1919 (15.5) |         |         |  |
| Vomiting                                           |       |              |             |         |         |  |
| No                                                 | 46550 | 38866 (83.5) | 7684 (16.5) | 15.44   | < 0.001 |  |
| Yes                                                | 7882  | 6440 (81.7)  | 1442 (18.3) |         |         |  |
| Nausea                                             |       |              |             |         |         |  |
| No                                                 | 46059 | 38167 (82.9) | 7892 (17.1) | 29.16   | < 0.001 |  |
| Yes                                                | 8373  | 7139 (85.3)) | 1234 (14.7) |         |         |  |
| Diarrhea                                           |       |              |             |         |         |  |
| No                                                 | 50516 | 41852 (82.8) | 8664 (17.2) | 74.63   | < 0.001 |  |
| Yes                                                | 3916  | 3454 (88.2)  | 462 (11.8)  |         |         |  |
| Headache                                           |       |              |             |         |         |  |
| No                                                 | 24125 | 19958 (82.7) | 4167 (17.3) | 7.97    | 0.005   |  |
| Yes                                                | 30307 | 25348 (83.6) | 4959 (16.4) |         |         |  |
| Joint pain                                         |       |              |             |         |         |  |
| No                                                 | 40925 | 33930 (82.9) | 6995 (17.1) | 12.59   | < 0.001 |  |
| Yes                                                | 13507 | 11376 (84.2) | 2131 (15.8) |         |         |  |
| Fever ≥38°C                                        |       |              |             |         |         |  |
| No                                                 | 13353 | 10986 (82.3) | 2367 (17.7) | 11.70   | < 0.001 |  |
| Yes                                                | 41079 | 34320 (83.5) | 6759 (16.5) |         |         |  |
| History of close contact with a symptomatic person |       |              |             |         |         |  |
| Sex Female                                         |       |              |             |         |         |  |
| No                                                 | 18939 | 16488 (87.1) | 2451 (12.9) | 1022.46 | < 0.001 |  |
| Yes                                                | 5661  | 3895 (68.8)  | 1766 (31.2) |         |         |  |
| Sex Male                                           |       |              |             |         |         |  |
| No                                                 | 22488 | 19831 (88.2) | 2657 (11.8) | 1430.75 | < 0.001 |  |
| Yes                                                | 7344  | 5092 (69.3)  | 2252 (30.7) |         |         |  |
| History of contact with a confirmed COVID-19 case  |       |              |             |         |         |  |
| Sex Female                                         |       |              |             |         |         |  |
| No                                                 | 18309 | 16071 (87.8) | 2238 (12.2) | 1219.53 | 0.001   |  |
| Yes                                                | 6291  | 4312 (68.5)  | 1979 (31.5) |         |         |  |
| Sex Male                                           |       |              |             |         |         |  |
| No                                                 | 23526 | 20561 (87.4) | 2965 (12.6) | 1201.47 | 0.001   |  |
| Yes                                                | 6306  | 4362 (69.2)  | 1944 (30.8) |         |         |  |

Quarterly trends RAT-based detection were visualized after Min–Max normalization, applied exclusively to facilitate graphical interpretation (Figure 6). The normalized showed substantial fluctuations during the first four quarters, with notable peaks in the second and fourth quarters. These peaks align with the third and fourth waves of the SARS-CoV-2 epidemic in the country. A pronounced and sustained decline was observed from the fifth quarter onward, with normalized values remaining consistently low through the eighth quarter, corresponding to the end of the epidemic period. The fitted linear trend demonstrates an overall downward trajectory in relative detection levels over time. Additionally, the residuals showed a progressive decrease across the observation sequence, indicating that the data are consistent with a decreasing linear multiplicative pattern. (Figure 6). No statistical comparison or quantitative inference was performed on normalized data.




Figure 6. Description analysis of trends in positive case detection by RATs after min-max Scaler normalization.

4. Discussion

This study evaluated the operational and epidemiological contribution of RATs in decentralization of COVID-19 diagnosis in Kinshasa.

It did not assess diagnostic performance, making its data not directly comparable. The study also presents certain methodological limitations and biases that may have influenced the interpretation of the results.

Indeed, several confounding factors and selection biases were considered when analyzing data from the rapid antigen tests (RATs). Since most of the included subjects were symptomatic or identified as contacts of suspected or confirmed cases, the apparent sensitivity of rapid tests may have been overestimated, as viral load is generally higher in this population.

Conversely, the low proportion of asymptomatic individuals—particularly in areas with limited testing coverage—combined with logistical disparities between health zones and periodic stock shortages, limits the generalizability of the findings to the entire population of Kinshasa.

In addition, the successive emergence of different variants (Alpha, Delta, Omicron) represents another confounding factor influencing the average viral load. Individual clinical characteristics, such as age, vaccination status, and comorbidities, may also modulate viral load and, consequently, the likelihood of antigen detection.

Finally, the operational conditions at testing sites — including staff training, sample quality, and adherence to testing procedures — may have contributed to the variability observed in the results. It should also be noted that the study does not provide separate data on negative RAT results obtained from symptomatic COVID-19 cases that were referred for RT-PCR confirmation.

Most subjects tested were in the 21–40 age group. The highest positivity rate was observed in those aged ≤21 (19.1%), despite their low representation. This trend could be explained by high social mobility and lower compliance with preventive measures among young people, who are often asymptomatic but highly exposed. This highlights the importance of active inclusion of youth in testing strategy to curb transmission. Our trends are in line with most African studies, in which the population was young [21].

We found more males in our study, although positivity rate was slightly higher in females. This finding could be explained by the role played by immunity (higher production of type 1 interferon

and T lymphocytes), hormones (the protective role of oestradiol), and genetic (the double X chromosome) encoding for the SARS-CoV-2 S protein [22–25].

Symptoms frequently associated with a positive RATs included fever  $\geq 38^{\circ}\text{C}$ , headache, sore throat, rhinorrhea and asthenia. Several studies have also reported fever  $\geq 38^{\circ}\text{C}$  as the dominant symptom, followed by cough [26–28]. Rhinorrhea showed a strong correlation with positivity of RATs. This could probably be linked to the disruption of the nasal microbiota induced by the virus [29].

In contrast, dyspnea was not statistically associated with positivity, suggesting their lack of sensitivity for SARS-CoV-2 prediction. Of note, other chronic or acute respiratory affections could have also induced this symptom. Our results are consistent with findings from Nkwembe et al. [30], who showed that SARS-CoV-2 accounted for only 19.2% of respiratory viruses detected during the pandemic, suggesting a possible underestimation of other respiratory aetiologies.

The use of RATs has become widespread in almost all health zones (HZ) in Kinshasa. This large-scale use testifies the extent of the decentralization strategy for Covid-19 diagnosis, which has 1) brought the diagnostic tool close to the community, 2) decreased the workload on reference laboratories, and 3) prompted the rapid implementation of medical countermeasures in line with WHO recommendations [7–11]. This strategy has also improved the quality and completeness of surveillance data, thereby limiting the risks of under-detection and the spread of the virus. Indeed, each undiagnosed case can lead to several infections in the absence of adequate countermeasures [31–33].

The Barumbu health zone recorded the highest positivity rate with RATs (37.8%). This situation could be explained by its proximity to the Gombe township, the initial epicenter of the pandemic in Kinshasa, from where transmission has spread to adjacent areas.

Our data showed that 54,432 suspected cases (48.9%) were tested with RATs. Our RATs use rate is close to that observed in France in 2021 (49%) during the initial rollout of these tests, before reaching 61% in 2022 due to the intensification of screening [34]. This proportion reflects the significant augmentation of screening access, especially in a limited resources setting.

Their use as a first-line test has enabled rapid detection, quick public-health decision making to streamline response actions, including in remote areas. Our findings support that RATs can be useful as a screening tool in facilities without RT-PCR capacity. However, their poor performance suggests that they should be used as a complementary tool to the RT-PCR, particularly to confirm negative cases during outbreak context. This strategy clearly ensures the reliability of the diagnosis and reduces the risk of false negatives.

The analysis of the temporal and spatial trends in SARS-CoV-2 positive case detection after normalization of quarterly data demonstrated the significant contribution of RATs to epidemiological surveillance, particularly during the third and fourth waves of the epidemic. They remained active until the end of the epidemic in our country.

Our findings are consistent with Jeanne-Marie Dozol data, in which large-scale testing showed high effectiveness of RATs [34].

Nonetheless, non-pharmaceutical and pharmaceutical measures (masks, social distancing, hand hygiene, limiting gatherings, vaccination) also played a crucial role in the disease control, as shown in several studies [35–37].

However, due to its originality, this research work has several strengths that automatically make it indisputably strong.

It covers a broad geographical area, within a relatively long timeframe, and over several Covid-19 waves. Therefore, our findings reinforce the study representativeness and robustness. This study has highlighted the role played by field data collected in real time to support the implementation of RATs. It also provides accurate operational characteristics of RATs use in outbreak settings, with highly valuable data generated to guide decision-making during emergencies. This study provides essential information for limited resources settings in support to the decentralization of diagnostic

tools. Study findings can also guide future screening strategies during outbreaks and other emergencies.

## 5. Conclusion

This study demonstrated broad geographical and temporal coverage of RATs in all health zones under the jurisdiction of the Kinshasa Provincial Health Department (DPS), and spanned a long period covering several successive epidemic waves.

It accurately reflects not only operational practices in a health crisis context, but also the diagnostic value of taking into account symptoms and contact tracing. This makes its results extremely valuable in guiding public health policy decisions in emergency situations, with a view to breaking the chain of transmission of SARS-CoV-2 or other exponentially spreading diseases.

The evaluation of the strategy of decentralizing diagnosis through the use of RATs has provided concrete data that can be transposed to other contexts facing similar difficulties in accessing RT-PCR. It thus helps to guide future testing strategies in the event of a resurgence of COVID-19 or the emergence of new respiratory threats for countries with limited resources.

**Author Contributions:** Conceptualization: Boniface Kaputa Kabala, Steve Ahuka Mundeke and Edith Nkwembe Ngabana; Methodology: Boniface Kaputa Kabala, Daniel Mukadi Bamuleka, Julien Neze Sebakunzi, Arthur Tshimuanga Kabuamba and Edith Nkwembe Ngabana; Formal analysis: Boniface Kaputa Kabala, Julien Neze Sebakunzi, Steve Ahuka Mundeke and Edith Nkwembe Ngabana; Investigation: Boniface Kaputa Kabala, Fiston Mboma Matalampaka, Delphine Mbonga Mande, Lisa Lebo Nsimba, Youdhie Ituneme N'kaflabo, François Kahwata Mawika; Resources: Boniface Kaputa Kabala, Steve Ahuka Mundeke and Edith Nkwembe Ngabana; Writing original draft preparation: Boniface Kaputa Kabala and Edith Nkwembe Ngabana; Data curation: Boniface Kaputa Kabala and Edith Nkwembe Ngabana; Writing review & editing: Daniel Mukadi Bamuleka, Julien Neze Sebakunzi, Arthur Tshimuanga Kabuamba, Trésor Kabeya Mampuela, Jean Paul Kompany Kisenzele, Juslin Ntambwe Kaneyi, Steve Ahuka Mundeke, Edith Nkwembe Ngabana; Visualization: Boniface Kaputa Kabala; Administration of the response: Secrétariat du Comité Multisectoriel de la Riposte contre la Covid-19 and Health District Office (DPS) of Kinshasa; Supervision: Steve Ahuka Mundeke and Edith Nkwembe Ngabana. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded in part by the International Research Platform on Global Health DR CONGO (PRISME/DRC).

**Institutional Review Board Statement:** This study was conducted as a part of the Covid-19 response led by the Secrétariat Technique du Comité Multisectoriel de la Riposte contre la Covid-19. Therefore, it did not require an ethical approval, though a formal letter of authorization was issued by the Health District Office (DPS) of Kinshasa and the Incident Manager of the Covid-19 response.

**Informed Consent Statement:** Informed consent and assent was obtained from all subjects involved in the study.

**Data Availability Statement:** The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding authors. However, additional questions relating to the data can be addressed to us if necessary.

**Acknowledgments :** We would like to wholeheartedly thank the authorities of the Kinshasa Provincial Health Division for agreeing to grant us permission to conduct our study within its jurisdiction. To the incident manager of the Multisectoral Covid-19 Response Committee and its Committee for granting us access to the database. To the Microbiology Department of the Kinshasa University Clinics and Dr. Nestor Mukinay Dizal for their scientific advice.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Na Zhu, Dingyu Zhang, Wenling Wang, Xingwang Li, Bo Yang, Jingdong Song et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019, *N Engl J Med* 2020; 382 :727-733.
2. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol.* 2022 May ;20(5) :141-154.
3. Otshudiema JO, Folefack GLT, Nsio JM, Mbala-Kingebeni P, Kakema CH, Kosianza JB et al. Epidemiological Comparison of Four COVID-19 Waves in the Democratic Republic of the Congo, March 2020-January 2022, *J Epidemiol Glob Health* 2022 Sep ;12 :316-327.
4. Mansourabadi AH, Sadeghalvadi M, Mohammadi-Motlagh HR, Amirzargar A. Serological and Molecular Tests for COVID-19: a recent update, *Iran J Immunol*; 2021 Mar ;18:13-33.
5. Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H et al. SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations. *Anal Bioanal Chem.* 2021 Jan ;413 :49-71.
6. Organisation Mondiale de la Santé (2020). Tests diagnostiques pour le dépistage du SARS-CoV-2 : Orientations provisoires 11 septembre 2020. Organisation mondiale de la Santé. <https://iris.who.int/handle/10665/335724>. License: CC BY-NC-SA 3.0 IGO (accessed on 15 April 2025).
7. Organisation Mondiale de la Santé (OMS). Détection des antigènes à l'aide de tests immunologiques rapides pour le diagnostic de l'infection à SARS-CoV-2, Orientations provisoires 11 septembre 2020. Available online : <https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays> (accessed on 29 August 2025).
8. WHO. Antigen\_Detection in the Diagnosis of SARS-CoV-2 Infection ; WHO : Geneva, Switzerland, 2021. [Google Scholar].
9. Guillaume CLOP, Impact du test antigénique de dépistage rapide du SARS-CoV2 sur le temps de passage des patients atteints de Covid-19 dans un service d'urgence, Université de Bordeaux, U.F.R. des Sciences médicales, Thèse n°3202, 2022, p.1-28.
10. Mukadi-Bamuleka D, Bulabula-Penge J, Jacobs BKM, De Weggheleire A, Edidi-Atani F, Mambu-Mbika F et al. Head-to-head comparison of diagnostic accuracy of four Ebola virus disease rapid diagnostic tests versus GeneXpert® in eastern Democratic Republic of the Congo outbreaks: a prospective observational study. *EBioMedicine.* 2023 May; 91:104568. doi: 10.1016/j.ebiom.2023.104568.
11. Mukadi-Bamuleka D, Bulabula-Penge J, De Weggheleire A, Jacobs BKM, Edidi-Atani F, Mambu-Mbika F Et al. Field performance of three Ebola rapid diagnostic tests used during the 2018-20 outbreak in the eastern Democratic Republic of the Congo: a retrospective, multicenter observational study. *Lancet Infect Dis.* 2022 Jun;22(6):891-900.
12. Organisation Mondiale de la Santé (OMS). Orientations pour la lutte anti-infectieuse dans les établissements de soins de longue durée dans le contexte de la COVID-19, Orientations provisoires 21 mars 2020. Available online : [https://apps.who.int/iris/bitstream/handle/10665/331642/WHO-2019-nCoV-IPC\\_long\\_term\\_care-2020.1-fre.pdf](https://apps.who.int/iris/bitstream/handle/10665/331642/WHO-2019-nCoV-IPC_long_term_care-2020.1-fre.pdf) (accessed on 29 August 2025).
13. Organisation mondiale de la Santé (OMS). Orientations pour la lutte anti-infectieuse dans les établissements de soins de longue durée dans le contexte de la Covid-19, orientations provisoires 8 janvier 2021. Available online : <https://iris.who.int/handle/10665/338935> (accessed on 15 April 2025).
14. World Health Organization (WHO). Prevention, Identification and Management of Health Worker Infection in the Context of COVID-19 ; 2020. Available online: <https://www.who.int/publications/i/item/10665-336265>. [Google Scholar]
15. République Démocratique du Congo, Ministère de la Santé, Hygiène et Prévoyance sociale, Comité Multisectoriel de la lutte contre la COVID-19 RDC. , Procédures opérationnelles de la Surveillance Épidémiologique de la COVID-19 centrée sur la Recherche active des cas, de la détection précoce des alertes et des cas suspects, à l'isolement et prise en charge médicale rapide des cas confirmés et au suivi des contacts, Décembre 2020
16. World Health Organization: WHO COVID-19 case definition. Available online : [https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Surveillance\\_Case\\_Definition-2020.2](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2). Accessed February 18, 2021 (accessed on 28 Mai 2025).

17. Vanessa Agulló, Marta Fernandez-González, Victoria Ortiz de la Tabla, Nieves Gonzalo-Jiménez, José A García, Mar Masiá, Félix Gutiérrez, Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study, *J Infect* 2020 Dec 9 ;82 :186–230.
18. Alemany A, Baró B, Ouchi D, Rodó P, Ubals M, Corbacho-Monné M et al. Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test, *J Infect* 2021 May ;82 : 186230.
19. Haute Autorité de Santé (HAS), Revue rapide sur les tests de détection antigénique du virus SARS-CoV-2, 8 Octobre 2020. Available online : <https://www.has-sante.fr> (accessed on 15 June 2025).
20. Haute Autorité de Santé (HAS), Évaluation de l'intérêt des tests antigéniques rapides sur le prélèvement nasal pour la détection du virus SARS-CoV-2 (Méta-analyse) avril 2021. Available online : <https://www.has-sante.fr> (accessed on 15 June 2025).
21. É.J.L. Hardy et P. Flori, Spécificités épidémiologiques de la COVID-19 en Afrique : préoccupation de santé publique actuelle ou future ? *Ann Pharm Fr.* 19 oct. 2020 ;79 :216–226.
22. Klein, S.L.& Flanagan, K.L. (2016). Sex differences in immune response, *Nature Reviews Immunology*, 16(10), 626–638.
23. Pison, G., & Meslé, F. (2022). La Covid-19 plus meurtrière pour les hommes que pour les femmes, *Population et Santé*, Institut National d'Études Démographiques, Mars 2022, 598 : 1-5.
24. Bornfleth, I., Kutschka, A. Gardemann, B. Isermann & Goette, A. (2017). Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. *Experimental Biology and Medicine* (Maywood), 242(14), 1412–1423.
25. Gebhard C., Regitz-Zagrosek V., Neuhauser HK, et al. Impact du sexe et du genre sur l'évolution de la COVID-19 en Europe. *Biol Sex Differ.* 2020 ; 11(1) : 29. doi : 10.1186/s13293-020-00304-9.
26. Plaçais L, Richier Q. COVID-19 : caractéristiques cliniques, biologiques et radiologiques chez l'adulte, la femme enceinte et l'enfant. Une mise au point de la pandémie. *Rev Med Interne*, 2020 Apr 17 ;41 :308–318.
27. Chow EJ, Schwartz NG, Tobolowsky FA, add authors to make 6 et al. Symptom screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King Country, *JAMA*. April 17, 2020;323:2087–2089.
28. JC Yombi, J De Greef, AS Marsin, A Simon, H Rodriguez-Villalobos, A Penalzoza, L Belkhir Symptom-based screening for COVID-19 in healthcare workers: the importance of fever, *YJHIN* 2020 July ;105:428–429.
29. Nikaia Smith, Pedro Goncalves, Bruno Charbit, Ludivine Grzelak, Maxime Beretta, Cyril Planchais et al. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection, *Nature Immunology* 01 September 2021, 22 :1428–1439.
30. Nkwembe EN, Ituneme YN, Mufwaya GM, Lebo LN, Matondo MK, Yalungu HM et al. Impact of COVID-19 on the Circulation of Respiratory Viruses in Kinshasa: Analysis of the Prevalence and Viral Etiologies of Acute Respiratory Infections, *Ojepi*, 2024 November, 14: 669–682.
31. Ying Liu, Albert Gayle, Annelies Wilder-Smith, Joacim Rocklöv. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Travel Med.* 13 Mar 2020;27 :1–4.
32. Billah M.A, Miah M.M, Khan M.N. Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence. *PLoS ONE*, November 11, 2020;15 :1–17.
33. Mai, N.T. ; Tran, G.T.H. ; Dang, A.H. ; Cao, P.T.B. ; Nguyen, T.T. ; Pham, H.T.L. ; Vu, T.T.T. ; Dong, H.V. ; Huynh, L.T.M. Comparison of the Basic Reproduction Numbers for COVID-19 through Four Waves of the Pandemic in Vietnam. *Int. J. Transl. Med.* 2023, 3, 1–11.
34. Jeanne-Marie Dozol. Place des tests antigéniques dans le dépistage et la stratégie diagnostique de la COVID-19 : retour d'expérience de pharmaciens d'officine de la Région SUD. *Sciences du Vivant [q-bio]*. 2025. (dumas-04957403)
35. Iris Ganser, David L. Buckeridge, Jane Heffernan, Mélanie Prague, Rodolphe Thiébaud. Estimating the population effectiveness of interventions against COVID-19 in France: A modelling study. *Epidemics*, March 2024; 46 :1–8.

36. Jingyuan Wang, Ke Tang, Kai Feng, Xin Lin, Weifeng Lv, Kun Chen, Fei Wang, Impact of temperature and relative humidity on the transmission of COVID-19: a modelling study in China and the United States. *BMJ Open* 2021 ;11 :1-16.
37. C Zheng, W Shao, X Chen, B Zhang, G Wang, W Zhang. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. *IJIDiseases*, January 2022; 114: 252–260.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.